Literature DB >> 27220331

Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat.

Dominik Steubl1, Martin C Michel2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27220331     DOI： 10.1007/s00210-016-1260-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  28 in total

1.  THE RENAL LESION IN GOUT.

Authors:  H C GONICK; M E RUBINI; I O GLEASON; S C SOMMERS
Journal:  Ann Intern Med       Date:  1965-04       Impact factor: 25.391

2.  Uric acid and chronic kidney disease: new understanding of an old problem.

Authors:  Duk-Hee Kang; Wei Chen
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

3.  Febuxostat Prevents Renal Interstitial Fibrosis by the Activation of BMP-7 Signaling and Inhibition of USAG-1 Expression in Rats.

Authors:  Jing Cao; Yong Li; Yingxian Peng; Yaqian Zhang; Huanhuan Li; Ran Li; Anzhou Xia
Journal:  Am J Nephrol       Date:  2015-12-18       Impact factor: 3.754

4.  Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.

Authors:  Kyle E Rodenbach; Michael F Schneider; Susan L Furth; Marva M Moxey-Mims; Mark M Mitsnefes; Donald J Weaver; Bradley A Warady; George J Schwartz
Journal:  Am J Kidney Dis       Date:  2015-07-21       Impact factor: 8.860

5.  Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy.

Authors:  Hiroki Omori; Noritaka Kawada; Kazunori Inoue; Yoshiyasu Ueda; Ryohei Yamamoto; Isao Matsui; Jyunya Kaimori; Yoshitsugu Takabatake; Toshiki Moriyama; Yoshitaka Isaka; Hiromi Rakugi
Journal:  Clin Exp Nephrol       Date:  2012-02-18       Impact factor: 2.801

6.  Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.

Authors:  Laura G Sánchez-Lozada; Edilia Tapia; Virgilia Soto; Carmen Avila-Casado; Martha Franco; Jerry L Wessale; Lin Zhao; Richard J Johnson
Journal:  Nephron Physiol       Date:  2008-04-24

7.  Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.

Authors:  Dipankar Sircar; Soumya Chatterjee; Rajesh Waikhom; Vishal Golay; Arpita Raychaudhury; Suparna Chatterjee; Rajendra Pandey
Journal:  Am J Kidney Dis       Date:  2015-07-30       Impact factor: 8.860

8.  Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.

Authors:  Yugo Shibagaki; Iwao Ohno; Tatsuo Hosoya; Kenjiro Kimura
Journal:  Hypertens Res       Date:  2014-06-19       Impact factor: 3.872

9.  Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.

Authors:  Alaa N A Fahmi; George S G Shehatou; Abdelhadi M Shebl; Hatem A Salem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-23       Impact factor: 3.000

Review 10.  Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.

Authors:  Tahir Kanji; Mandark Gandhi; Catherine M Clase; Robert Yang
Journal:  BMC Nephrol       Date:  2015-04-19       Impact factor: 2.388
View more
  1 in total

1.  Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.

Authors:  Tunlanut Sapankaew; Kunlawat Thadanipon; Narisa Ruenroengbun; Kamolpat Chaiyakittisopon; Atiporn Ingsathit; Pawin Numthavaj; Nathorn Chaiyakunapruk; Gareth McKay; John Attia; Ammarin Thakkinstian
Journal:  BMC Nephrol       Date:  2022-06-23       Impact factor: 2.585
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.